Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 in Major Depressive Disorder
NCT06419608Phase 2Completed
- Sponsor
- Biohaven Ltd.
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of opakalim in major depressive disorder (MDD), sponsored by Biohaven Ltd.. Started May 2024; status: completed.
02
Drugs
opakalim
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06419608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419608.